应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
ARGX Argenx SE
盘前交易 09-02 09:08:15 EDT
1,028.51
-3.15
-0.31%
盘前
1,044.87
+16.36
+1.59%
08:32 EDT
最高
1,039.13
最低
1,021.55
成交量
19.29万
今开
1,033.36
昨收
1,031.66
日振幅
1.70%
总市值
643.21亿
流通市值
642.30亿
总股本
6,254万
成交额
1.98亿
换手率
0.31%
流通股本
6,245万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读｜Argenx SE盘中上涨3.06%，肌炎三期数据催化延续叠加机构上调目标价
行情直击 · 08-27
异动解读｜Argenx SE盘中上涨3.06%，肌炎三期数据催化延续叠加机构上调目标价
异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价
行情直击 · 08-26
异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价
Argenx（ARGX）股价走高遭评级下调 新药商业化预期成为博弈焦点
金吾财讯 · 08-24
Argenx（ARGX）股价走高遭评级下调 新药商业化预期成为博弈焦点
异动解读｜Argenx SE盘中上涨3.17%，多家投行上调评级确认肌炎数据利好
行情直击 · 08-19
异动解读｜Argenx SE盘中上涨3.17%，多家投行上调评级确认肌炎数据利好
异动解读｜Argenx SE夜盘下跌3.83%，报950.02美元
行情直击 · 08-18
异动解读｜Argenx SE夜盘下跌3.83%，报950.02美元
美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%
老虎资讯综合 · 08-17
美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%
异动解读｜Argenx SE盘中上涨9.45%，核心药物efgartigimod三期临床试验达主要终点
行情直击 · 08-17
异动解读｜Argenx SE盘中上涨9.45%，核心药物efgartigimod三期临床试验达主要终点
美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点
智通财经 · 08-17
美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点
美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功
中金财经 · 08-17
美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功
异动解读｜Argenx SE盘前上涨5%，核心药物三期临床试验达主要终点
行情直击 · 08-17
异动解读｜Argenx SE盘前上涨5%，核心药物三期临床试验达主要终点
Argenx三期临床试验传佳音，efgartigimod治疗自身免疫性肌炎达主要终点，盘前股价升逾7%
老虎资讯综合 · 08-17
Argenx三期临床试验传佳音，efgartigimod治疗自身免疫性肌炎达主要终点，盘前股价升逾7%
argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果
金吾财讯 · 08-17
argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果
Argenx SE（ARGX）正式发起要约收购 拟全现金吞并Forte（FBRX）
金吾财讯 · 08-06
Argenx SE（ARGX）正式发起要约收购 拟全现金吞并Forte（FBRX）
异动解读｜Argenx SE盘中下跌3.01%，豪掷22亿美元现金收购Forte Biosciences引发市场消化
行情直击 · 07-28
异动解读｜Argenx SE盘中下跌3.01%，豪掷22亿美元现金收购Forte Biosciences引发市场消化
Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合
智通财经 · 07-27
Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合
Argenx豪掷22亿美元、溢价40%收购Forte Biosciences
老虎资讯综合 · 07-27
Argenx豪掷22亿美元、溢价40%收购Forte Biosciences
异动解读｜Argenx SE盘中上涨6.88%，Q2业绩大幅超预期推动股价走强
行情直击 · 07-24
异动解读｜Argenx SE盘中上涨6.88%，Q2业绩大幅超预期推动股价走强
异动解读 | 财报业绩强劲，Argenx SE盘中大涨5.33%
异动解读 · 07-23
异动解读 | 财报业绩强劲，Argenx SE盘中大涨5.33%
异动解读 | Q2业绩强劲增长，Argenx SE盘前大涨5.17%
异动解读 · 07-23
异动解读 | Q2业绩强劲增长，Argenx SE盘前大涨5.17%
argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%
金吾财讯 · 07-23
argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%
加载更多
公司概况
公司名称：
Argenx SE
所属市场：
NASDAQ
上市日期：
--
主营业务：
Argenx Se根据荷兰法律于2008年4月25日成立，是一家私人有限责任公司（besloten vennootschap met beperkte aansprakelijkheid）。 于2014年5月28日，根据公证转换契约及修订，该公司转为上市有限责任公司（naamloze vennootschap）。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。
发行价格：
--
{"stockData":{"symbol":"ARGX","market":"US","secType":"STK","nameCN":"Argenx SE","latestPrice":1028.51,"timestamp":1788292800000,"preClose":1031.66,"halted":0,"volume":192944,"hourTrading":{"tag":"盘前","latestPrice":1044.87,"preClose":1028.51,"latestTime":"08:32 EDT","volume":129,"amount":134727.6,"timestamp":1788352337178,"change":16.36,"changeRate":0.015907,"amplitude":0.014429},"delay":0,"changeRate":-0.0030533315239517776,"floatShares":62449100,"shares":62537923,"eps":26.213955,"marketStatus":"盘前交易","change":-3.15,"latestTime":"09-02 09:08:15 EDT","open":1033.36,"high":1039.13,"low":1021.5501,"amount":198448132.7824,"amplitude":0.01704,"askPrice":1045.85,"askSize":10,"bidPrice":1044.78,"bidSize":30,"shortable":3,"etf":0,"ttmEps":26.213955,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788355800000},"marketStatusCode":1,"adr":1,"adrRate":1,"listingDate":1495080000000,"exchange":"NASDAQ","adjPreClose":1028.51,"preHourTrading":{"tag":"盘前","latestPrice":1044.87,"preClose":1028.51,"latestTime":"08:32 EDT","volume":129,"amount":134727.6,"timestamp":1788352337178,"change":16.36,"changeRate":0.015907,"amplitude":0.014429},"postHourTrading":{"tag":"盘后","latestPrice":1028.51,"preClose":1028.51,"latestTime":"19:30 EDT","volume":30579,"amount":31450738.57,"timestamp":1788305406522,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7840963495286031,"impliedVol":0.3936,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/ARGX","defaultTab":"news","newsList":[{"id":"1146034637","title":"异动解读｜Argenx SE盘中上涨3.06%，肌炎三期数据催化延续叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1146034637","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146034637?lang=zh_cn&edition=full","pubTime":"2026-08-27 00:13","pubTimestamp":1787760797,"startTime":"0","endTime":"0","summary":"8月26日，Argenx SE盘中上涨3.06%，报1050.73美元/股，成交额1.5亿美元。消息面上，公司核心产品Vyvgart Hytrulo治疗自身免疫性肌炎的三期ALKIVIA试验此前达到主要终点，多家机构持续给予积极评价。Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次上涨或为前一交易日回调后的修复性反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Argenx肌炎数据催化，盘中强势上扬","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182552700","title":"异动解读｜Argenx SE盘前上涨3.85%，肌炎三期数据催化延续叠加机构上调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1182552700","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182552700?lang=zh_cn&edition=full","pubTime":"2026-08-26 18:41","pubTimestamp":1787740883,"startTime":"0","endTime":"0","summary":"8月26日，Argenx SE盘前上涨3.85%，报1058.75美元/股，成交额25.34万美元。多家机构对此给出积极评价，Wedbush将目标价上调至1150美元，RBC、Morgan Stanley及Oppenheimer均认为该数据降低了Vyvgart约15至20亿美元肌炎市场机会的不确定性。公司此前二季度营收15.42亿美元超预期7%，EPS 7.32美元超预期17%，基本面持续强劲。此次盘前上涨或为前一交易日回调后的修复性反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"肌炎三期数据获机构力挺，Argenx盘前上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661427725","title":"Argenx（ARGX）股价走高遭评级下调 新药商业化预期成为博弈焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2661427725","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661427725?lang=zh_cn&edition=full","pubTime":"2026-08-24 23:18","pubTimestamp":1787584698,"startTime":"0","endTime":"0","summary":"同时机构重点关注在研药物empasiprubart用于罕见肌肉运动障碍多灶性运动神经病变的三期EMPASSION临床试验，虽然对试验结果保持乐观，但判断这条管线不确定性更高，情绪扰动会更大，不足以支撑当前股价位置继续进一步加仓。市场已经充分反应核心药物临床利好，新适应症带来增量有限，后期需要重点跟踪empasiprubart三期试验读出结果，该管线成败将会显著影响公司长期估值。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305257","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FALN","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152195298","title":"异动解读｜Argenx SE盘中上涨3.17%，多家投行上调评级确认肌炎数据利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1152195298","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152195298?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:45","pubTimestamp":1787147114,"startTime":"0","endTime":"0","summary":"8月19日，Argenx SE盘中上涨3.17%，报1025.73美元/股，成交额2985.1万美元。消息面上，公司核心药物efgartigimod治疗自身免疫性肌炎的三期ALKIVIA试验达到主要终点后，多家华尔街投行密集发布看多研报。Oppenheimer指出该数据降低了Vyvgart在肌炎领域15亿至20亿美元市场机会的不确定性；RBC Capital Markets认为Vyvgart Hytrulo获FDA批准的可能性较高；Morgan Stanley表示数据强化了efgartigimod整体前景并上调成功概率假设；Wedbush将目标价从1050美元上调至1150美元并维持跑赢大盘评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143114221","title":"异动解读｜Argenx SE夜盘下跌3.83%，报950.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143114221","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143114221?lang=zh_cn&edition=full","pubTime":"2026-08-18 15:01","pubTimestamp":1787036493,"startTime":"0","endTime":"0","summary":"8月18日，Argenx SE夜盘下跌3.83%，报950.02美元/股，成交额1.27万美元。Argenx SE所在的生物科技行业中，个股涨跌不一，其中安进涨0.39%，艾伯维公司涨0.04%，福泰制药涨0.75%，吉利德科学涨0.04%，Revolution Medicines跌0.03%。Argenx SE是一家处于商业阶段的全球性生物制药公司，专注于开发用于治疗严重自身免疫性疾病的差异化疗法。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137019504","title":"美股开盘 | 三大指数涨跌不一，闪迪涨超3%，Argenx SE涨近9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1137019504","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137019504?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:32","pubTimestamp":1786973544,"startTime":"0","endTime":"0","summary":"8月17日，美股三大指数开盘涨跌不一，道琼斯指数跌0.23%，标普500指数涨0.04%，纳斯达克综合指数涨0.24%。美股存储股普涨，SK海力士、西部数据、闪迪涨超3%，美光科技、希捷科技涨超2%。OmniAb涨超23%，公司此前宣布与礼来达成3.7亿美元药物研发协议。Argenx SE涨近9%，Efgartigimod治疗肌炎III期试验成功。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDC","LU1778281490.HKD","LU1815336760.USD","LU2552382215.SGD","LU0256863902.USD","LU0323591593.USD","HRTS","AGNG","SH","LU1235294995.USD","IE00B19Z3B42.SGD","IE0001KFT4U8.USD","LU2236285917.USD","YMmain","LU0820561909.HKD","LU0127658192.USD","MMAX","LU2213496289.HKD","SG9999001176.USD","IE0004445239.USD","LU2237443549.SGD","LLII","LU2471134879.HKD","LU1064131342.USD","LU2237438978.USD","BK4585","CHPS","LU0823416689.USD","LU1720051108.HKD","LU0238689110.USD","HYNX","TMED","LU2102340556.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2271345857.HKD","BK4139","MEDX","LU2357627491.SGD","SKHU","LU2360107168.USD","IE00B7KXQ091.USD","QQQG","IE00B894F039.SGD","LU0471298694.HKD","FTEC","LU2286300806.USD","LU2403377893.USD","WDNA","IE00BWXC8680.SGD","BK4543","IE00B2B36J28.USD","LU0385154629.USD","LU0889566641.SGD","LU0006306889.USD","OPTZ","JGRO","LU0006061336.USD","TRUH","LU2491050154.USD","SOXQ","LU1127390331.HKD","BOBP","LU2087625088.SGD","IE00BFSS8Q28.SGD","LU0444973449.USD","XNTK","ILDR","WLDR","LU2468319806.SGD","WUGI","STX.AU","SPDN","LU1046421795.USD","BK4588","LU2237443382.USD","LU1093756325.SGD","LU1861215975.USD","COWG","LU2756315318.SGD","LU1720051017.SGD","SG9999014914.USD","PPH","THNR","LU0689472784.USD","AIQ","LU1917777945.USD","MUD","CURE","SKHA","SKHYV","LU1823568750.SGD","LU1868836757.USD","LU2931357623.SGD","LU2471134952.CNY","LU2361044865.SGD","SDS","BK4141","SG9999017495.SGD","SNDG","IE00B775H168.HKD","WDCX","LU2111349929.HKD","ARGX","BK4532","HBMX","LU0964807845.USD","LU0234572021.USD","LU1914381329.SGD","LU1861220033.SGD","BK4581","LU1674673691.USD","LU2462591350.SGD","LU0444971666.USD","BK4170","SG9999013999.USD","SNDU","LU1057294990.SGD","07709","IE00BJJMRY28.SGD","LU1803068979.SGD","LU2756315664.SGD","SG9999015986.USD","BK4505","SKHZ","LU1674673428.USD","BK4553","AIFD","HIBL","EGGY","LU2746668974.SGD","LLYZ","LU0787776722.HKD","IE00B19Z9Z06.USD","LU1989771016.USD","BK4512","IE0009356076.USD","LU1983299246.USD","LU1069347547.HKD","DIA","LU2471134796.USD","LU2552382058.USD","LU1804176565.USD","LU0079474960.USD","SKUU","LU0792757196.USD","BK4575","LU0109391861.USD","BK4007","LU0158827781.USD","SG9999001176.SGD","LU0354030438.USD","LU1989764748.USD","LU1366333091.USD","IE00BJJMRZ35.SGD","LU2491049909.HKD","LU1035773651.USD","SCHA","BK4579","LU2237443978.SGD","LU1670628061.USD","LU0266013472.USD","SPYU","LU2250418816.HKD",".SPX","IE00B4JS1V06.HKD","IE00B19Z9P08.USD","BK4554","SG9999018865.SGD","MULL","SGXZ99366536.SGD","LU1323610961.USD","SOXX","SGXZ81514606.USD","IE00BKPKM429.USD","LU0097036916.USD","FTXL","LU0289739699.SGD","TTXU","IE00B7SZLL34.SGD","LU1093756168.USD","LU2324357040.USD","LU0672654240.SGD","DDM","IE00B5949003.HKD","LU2746668461.USD","IE00BJLML261.HKD","SG9999014898.SGD","IE00B1BXHZ80.USD","LU0683600562.USD","LU0316494557.USD","LU2290526834.HKD","CNAV","LU2361045086.USD","BK4605","LU2089985449.USD","MEDI","DRMY","GB00BDT5M118.USD","DMAX","BK4534","LU0198837287.USD","LU2361044949.HKD","BK4566","IE000M9KFDE8.USD","SPXL","RXL","LU0072461881.USD","XLK","LU2471134523.USD","IBB",".IXIC","SG9999015952.SGD","SK","LU1267930813.SGD","LU0889565916.HKD","IE00BN29S564.USD","LU2089284900.SGD","LU0174119429.USD","LU0820562030.AUD","LU0882574139.USD",".DJI","LU1988902786.USD","IE0009355771.USD","LU0640476718.USD","SG9999015945.SGD","SPYM","IE00BFSS7M15.SGD","LU1267930730.SGD","SGXZ31699556.SGD","LU0943347566.SGD","TBXU","LU2211815571.USD","SDOW","MUYY","SPXU","LU2108987350.USD","LU2168564065.EUR","XLV","SG9999018857.SGD","SHOC","DISK","LU1983260115.SGD","AIS","IYH","LU2458330243.SGD","SNXX","LU0320765992.SGD","LU2168564495.EUR","IE00BJJMRX11.SGD","LU1069344957.HKD","SPYH","IE0005OL40V9.USD","LU2750360997.AUD","LU0240878834.USD","SKHX","LU0320765059.SGD","LU0820561818.USD","SNDK","LU0054578231.USD","LU2543165471.USD","LU1023059063.AUD","LU0456855351.SGD","LU0476273544.USD","FTXH","LU0719512351.SGD","FHLC","QQQA","LU0154236417.USD","SSO","LU2458330169.SGD","LU1642822529.SGD","VGT","LU1814569148.SGD","IVV","LU0823434583.USD","FXL","LU0889565833.HKD","GDOC","LU2264538146.SGD","LU0162691827.USD","LU0353189680.USD","SPXS","ARTY","LU2028103732.USD","LU0082616367.USD","RULE","LU2168564149.EUR","LU0466842654.USD","SNDC","LU2054465674.USD","LU2462157665.USD","BAI","BK4599","JDOC","LU1623119135.USD","IE00B4R5TH58.HKD","IE0002270589.USD","LU2456880835.USD","LU0094547139.USD","STX","LU0203202063.USD","LU0345770993.USD","LU1280957306.USD","LU2023251221.USD","LU1061106388.HKD","IE0002141913.USD","SPYQ","LU2237443895.HKD","IE00B19Z3581.USD","SNDQ","LU2461242641.AUD","IHE","TRFK","LU0158827948.USD","LU2106854487.HKD","LU2602419157.SGD","UDOW","VOO","LU0963586101.USD","PTF","LU1868836914.USD","LU1035775433.USD","SGXZ51526630.SGD","LU0106261372.USD","LU1979441026.SGD","BK4516","LU0096364046.USD","SKHY","USXF","LU2417539215.USD","LLY","DXD","FCUS","IE0004445015.USD","LU2089283258.USD","LU0274383776.USD","LU0109392836.USD","LU2237443622.USD","LU0058720904.USD","IE00BK4W5M84.HKD","CHPX","LU1551013425.SGD","BK7142","LU1974910355.USD","PSI","PJP","LU1868837300.USD","LU2491050071.SGD","LU0061475181.USD","LU0210536198.USD","LU1366192091.USD","LU1629891620.HKD","LU2168564222.USD","SG9999015978.USD","LU0471298777.SGD","LU0957808578.USD","LU1548497426.USD","FDTX","BK4527","SMU00main","IE0034235188.USD","LU1232071149.USD","MIC","LU0056508442.USD","IE00BJT1NW94.SGD","UPRO","IE00BSNM7G36.USD","FSMD","LU2112291526.USD","LU2023250504.SGD","LU2552382132.HKD","LU0823434740.USD","MU","DOG","LU0256863811.USD","EMSF","LU0859254822.USD","CANC","LU0353189763.USD","ELIS","LU1316542783.SGD","FAI","OZEM","LU0157215616.USD","LU2360106780.USD","CGGO","FMED","BK4533","SG9999001424.SGD","IETC","LU1291159041.SGD","MHIP","LU2357305700.SGD","SG9999014906.USD","LEGR","YSPY","MUU","LLYX","IXJ","LU2063271972.USD","SMH","SPY","TMSL","LU0642271901.SGD","LU1145028129.USD","EFIV","LU0114720955.EUR","LU0203347892.USD","LU0203345920.USD","LU0354030511.USD","LU0203201768.USD","IE00B1XK9C88.USD","LU2896262040.SGD","SMAX","LU0786609619.USD","LU0432979614.USD","LU1670627923.USD","LU1989764664.SGD","LU2023250330.USD","LU0081259029.USD","LU0708995401.HKD","LU0417517546.SGD","IE0034235303.USD","LU2265009873.SGD","LU2089984988.USD","LU0133085943.USD","LU0225283273.USD","LU2360106947.USD","SCHM","LU1712237335.SGD","ELIL","LU2048586759.USD","IE00BKDWB100.SGD","LU0345770308.USD","LU1868837136.USD","CHAT","LU2237443465.HKD","SGXZ57979304.SGD","SKDD","MUZ","IXN","LU1551013342.USD","LU0882574055.USD","LU0109394709.USD","CNEQ","LU1868836591.USD","LU0240877869.USD","SG9999014880.SGD","SPUU","LU1852331112.SGD","IE00BK4W5L77.USD","VHT","LU2168563687.JPY","LU2750360641.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169402008","title":"异动解读｜Argenx SE盘中上涨9.45%，核心药物efgartigimod三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1169402008","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169402008?lang=zh_cn&edition=full","pubTime":"2026-08-17 21:30","pubTimestamp":1786973435,"startTime":"0","endTime":"0","summary":"8月17日，Argenx SE盘中上涨9.45%，报931.73美元/股，成交额3068.0万美元。消息面上，公司宣布其药物efgartigimod在针对成人自身免疫性肌炎的三期ALKIVIA临床试验中达到主要终点。该试验也是全球首个在免疫介导性坏死性肌病这一无获批疗法的疾病亚型中取得显著改善的三期临床试验。此前RBC Capital Markets曾指出，肌炎数据是公司股价最大的潜在催化剂。公司二季度产品净销售额达15.16亿美元，同比增长60%，EPS为7.32美元，业绩基本面稳健。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660481020","title":"美股异动 | Argenx(ARGX.US)盘前涨超10% 自身免疫性肌炎药物Vyvgart III期研究达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2660481020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660481020?lang=zh_cn&edition=full","pubTime":"2026-08-17 18:48","pubTimestamp":1786963699,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0034235188.USD","BK4139","IBB","LU0109394709.USD","IE0002141913.USD","LU2324357040.USD","IE00BJJMRZ35.SGD","ARGX","IE00B2B36J28.USD","BK4585","BK4134","IE00B4R5TH58.HKD","BK4505","IE0009355771.USD","LU0889565916.HKD","LU0320765992.SGD","TBXU","IE00BFTCPJ56.SGD","FMED","IE00BJT1NW94.SGD","LU1983260115.SGD","III","BK4588","LU0823416689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660848605","title":"美股异动丨Argenx SE盘前大涨超7%，Efgartigimod治疗肌炎III期试验成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660848605","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660848605?lang=zh_cn&edition=full","pubTime":"2026-08-17 17:37","pubTimestamp":1786959424,"startTime":"0","endTime":"0","summary":"Argenx SE(ARGX.US)盘前涨超7%，报913.38美元。消息面上，公司宣布，Efgartigimod在治疗自身免疫性肌炎的III期ALKIVIA试验中达到了主要终点。在52周时，与安慰剂相比，药物在总改善评分(TIS) 上实现了具有统计学和临床意义的改善。此次试验成功对Argenx意义重大，开辟新市场：自身免疫性肌炎在美国影响约10万人，其中IMNM约2万，DM约4万，这是一个尚未被满足的巨大医疗市场。公司计划为IMNM提交加速审批申请，并将与FDA讨论DM的申报可能性。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/17/20260817706794.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260817/32337291.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4505","BK4134","IE00B4R5TH58.HKD","ARGX","LU0109394709.USD","LU0823416689.USD","FMED","IBB","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU2324357040.USD","IE00B2B36J28.USD","BK4588","IE0034235188.USD","LU1983260115.SGD","IE0009355771.USD","TBXU","III","BK4139","BK4585","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102460417","title":"异动解读｜Argenx SE盘前上涨5%，核心药物三期临床试验达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1102460417","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102460417?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:48","pubTimestamp":1786956516,"startTime":"0","endTime":"0","summary":"8月17日，Argenx SE盘前上涨5%，报919.35美元/股。消息面上，公司宣布其药物efgartigimod在一项针对成人自身免疫性肌炎的三期临床试验中达到主要终点，显示出对疾病活动度的显著改善。试验数据显示，接受efgartigimod治疗的患者在第52周时，平均总改善评分较安慰剂组高出15.4分，治疗获益早在第4周即显现并持续至整个52周治疗期。公司二季度产品净销售额达15.16亿美元，同比增长60%，EPS为7.32美元，均超市场预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118250475","title":"Argenx三期临床试验传佳音，efgartigimod治疗自身免疫性肌炎达主要终点，盘前股价升逾7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118250475","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118250475?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:44","pubTimestamp":1786956271,"startTime":"0","endTime":"0","summary":"免疫学公司$Argenx SE(ARGX)$周一盘前上涨逾7%，此前该公司宣布，其药物efgartigimod在一项针对成人自身免疫性肌炎的后期临床试验中达到主要终点，显示出对疾病活动度的显著改善。这项三期临床试验结果显示，efgartigimod在两种肌肉萎缩型疾病亚型中，相较安慰剂均取得了快速且持续的疗效，其中一种亚型目前尚无任何获批的治疗方案。与安慰剂组相比，接受efgartigimod治疗的患者在第52周时，平均总改善评分高出15.4分。此次研究也是首个在免疫介导性坏死性肌病(IMNM)这一目前缺乏获批疗法的疾病亚型中，展现出显著改善的三期临床试验。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Argenx三期临床试验传佳音，efgartigimod治疗自身免疫性肌炎达主要终点，盘前股价升逾7%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660853994","title":"argenx SE（ARGX）宣布Efgartigimod治疗自身免疫性肌炎的3期ALKIVIA试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2660853994","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660853994?lang=zh_cn&edition=full","pubTime":"2026-08-17 16:43","pubTimestamp":1786956188,"startTime":"0","endTime":"0","summary":"该试验评估了皮下注射药物VYVGART Hytrulo在成人自身免疫性肌炎中的疗效，包括免疫介导的坏死性肌病和皮肌炎。在IMNM亚组分析中，治疗组同样展现出14.8分的显著改善。这是全球首个在没有任何批准疗法的IMNM领域取得统计学显著与临床意义改善的三期临床试验。自身免疫性肌炎属于罕见且高度致残的疾病，长久以来临床严重依赖大剂量激素和广谱免疫抑制剂。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/OGE4NjMzOTE0MzMzMjk=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303846","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE0009355771.USD","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4505","TBXU","LU0823416689.USD","IE0002141913.USD","IE0034235188.USD","LU2324357040.USD","LU0889565916.HKD","ARGX","FMED","IE00BFTCPJ56.SGD","IBB","LU1983260115.SGD","IE00BJT1NW94.SGD","BK4139","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657314546","title":"Argenx SE（ARGX）正式发起要约收购 拟全现金吞并Forte（FBRX）","url":"https://stock-news.laohu8.com/highlight/detail?id=2657314546","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657314546?lang=zh_cn&edition=full","pubTime":"2026-08-06 20:37","pubTimestamp":1786019826,"startTime":"0","endTime":"0","summary":"Argenx拟以每股77.00美元的现金价格收购Forte所有已发行及流通在外的普通股，要约收购自2026年8月6日正式开启，将于美东时间2026年8月26日到期。不过，该交易还需要获得代表Forte已发行股份超50%的有效预先要约与接纳，也须符合美国HSR法案的等待期届满或提前终止。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/Mjk1NzA2YjQxMDg1MTQ0MjI1MzE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303516","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0823416689.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","ARGX","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","TBXU","IE00B2B36J28.USD","LU1983260115.SGD","BK4139","LU0320765992.SGD","FMED","FBRX","LU0889565916.HKD","IBB","IE0034235188.USD","BK4505","IE00B4R5TH58.HKD","IE0009355771.USD","LU2324357040.USD","EVNT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119188140","title":"异动解读｜Argenx SE盘中下跌3.01%，豪掷22亿美元现金收购Forte Biosciences引发市场消化","url":"https://stock-news.laohu8.com/highlight/detail?id=1119188140","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119188140?lang=zh_cn&edition=full","pubTime":"2026-07-28 03:57","pubTimestamp":1785182225,"startTime":"0","endTime":"0","summary":"消息面上，公司宣布将以每股77美元、总计约22亿美元的现金收购Forte Biosciences，溢价约40%。此次收购旨在将Forte的核心项目FB102纳入管线，拓展其免疫学药物组合，该项目针对乳糜泻的二期临床数据预计于下半年公布。尽管Wedbush将Argenx目标价从1000美元上调至1050美元，维持跑赢大盘评级，但作为收购方，大额现金支出及整合不确定性使股价短期承压，被收购方Forte Biosciences则大涨39.7%，呈现典型的并购交易双方股价分化格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654097843","title":"Argenx(ARGX.US)豪掷22亿美元、溢价40%收购Forte Biosciences(FBRX.US) 加码布局免疫学药物组合","url":"https://stock-news.laohu8.com/highlight/detail?id=2654097843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654097843?lang=zh_cn&edition=full","pubTime":"2026-07-27 14:52","pubTimestamp":1785135121,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","IE0034235188.USD","IBB","BK4505","LU1983260115.SGD","LU0109394709.USD","LU2324357040.USD","TBXU","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","ARGX","FMED","BK4139","FBRX","IE0009355771.USD","BK4585","LU0320765992.SGD","IE00B2B36J28.USD","LU0889565916.HKD","BK4588","IE0002141913.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145887507","title":"Argenx豪掷22亿美元、溢价40%收购Forte Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=1145887507","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145887507?lang=zh_cn&edition=full","pubTime":"2026-07-27 13:08","pubTimestamp":1785128915,"startTime":"0","endTime":"0","summary":"7月27日，ForteBiosciences美股夜盘飙升逾22%，Argenx将以每股77美元的价格对其进行现金收购。全球免疫学创新公司 argenx和Forte Biosciences, Inc.今天宣布，两家公司已达成最终协议，根据该协议，argenx 将以每股 77 美元的现金收购 Forte Biosciences，总股权价值约为 22 亿美元。Forte Biosciences 的主导项目 FB102 的加入，进一步拓展了 argenx 的差异化免疫学药物产品组合。此次收购体现了 argenx 严谨的研发策略，致力于为患者发现并推进突破性科学，以期重新定义数十年来缺乏实质性创新疗法的疾病的治疗标准。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Argenx豪掷22亿美元、溢价40%收购Forte Biosciences","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBRX","ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154039515","title":"异动解读｜Argenx SE盘中上涨6.88%，Q2业绩大幅超预期推动股价走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1154039515","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154039515?lang=zh_cn&edition=full","pubTime":"2026-07-24 00:12","pubTimestamp":1784823177,"startTime":"0","endTime":"0","summary":"7月23日，Argenx SE盘中上涨6.88%，报910.34美元/股，成交额2.53亿美元。消息面上，公司于当日盘前发布第二季度财报，业绩大幅超出市场预期。季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。基本面来看，核心产品Vyvgart在获得FDA全血清型适应症扩展批准后处方转化持续放量，CIDP患者份额预期从18%升至23%，叠加公司截至6月底拥有52亿美元现金储备，为后续研发及商业化扩张提供充裕资金支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119182867","title":"异动解读 | 财报业绩强劲，Argenx SE盘中大涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1119182867","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119182867?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:10","pubTimestamp":1784815835,"startTime":"0","endTime":"0","summary":"Argenx SE今日盘中大涨5.33%，引发市场广泛关注。消息面上，公司于盘前发布了2026年第二季度及上半年财报，业绩表现极为亮眼。数据显示，公司第二季度产品净销售额达到15.16亿美元，同比大幅增长60%，环比增长17%；季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。2026年上半年，公司产品净销售额累计达28.13亿美元，净利润达8.38亿美元，均较去年同期显著提升。强劲的业绩增长与积极的管线预期共同提振了市场信心，推动股价盘中走强。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166453652","title":"异动解读 | Q2业绩强劲增长，Argenx SE盘前大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166453652","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1166453652?lang=zh_cn&edition=full","pubTime":"2026-07-23 20:10","pubTimestamp":1784808637,"startTime":"0","endTime":"0","summary":"Argenx SE今日盘前大涨5.17%，引发市场广泛关注。消息面上，公司于盘前发布了2026年第二季度及上半年财报，业绩表现极为亮眼。数据显示，公司第二季度产品净销售额达到15.16亿美元，同比大幅增长60%，环比增长17%；季度净利润攀升至4.72亿美元，较去年同期的2.45亿美元近乎翻倍。强劲的业绩增长与积极的管线预期共同提振了市场信心，推动股价盘前走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653749341","title":"argenx(ARGX)二季度产品净销售额达15.16亿美元 同比增长60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653749341","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653749341?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:18","pubTimestamp":1784801894,"startTime":"0","endTime":"0","summary":"金吾财讯 | 全球自身免疫疾病龙头生物科技公司 argenx 发布了2026年第二季度及上半年财报。其中，2026年第二季度，公司实现产品净销售额 15.16亿美元，同比大幅增长 60%，环比增长 17%。资金储备方面，截至2026年6月30日，argenx 拥有的现金、现金等价物及流动金融资产达 52亿美元，显著高于2025年底的44亿美元，为后续临床研发及商业化扩张提供了雄厚的资金屏障。截至2026年底，argenx 预计将有10款药物分子处于临床研发阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ODM0ODU4NWZiOGY2NDQ4NTA4OTM0NDg5MTI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302939","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235188.USD","FMED","IBB","BK4139","LU1983260115.SGD","BK4505","ARGX","BK4585","LU0109394709.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","TBXU","IE0002141913.USD","LU0320765992.SGD","LU2324357040.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.argenx.com","stockEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.2046},{"period":"3month","weight":0.2649},{"period":"6month","weight":0.4126},{"period":"1year","weight":0.4441},{"period":"ytd","weight":0.223}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Argenx Se根据荷兰法律于2008年4月25日成立，是一家私人有限责任公司（besloten vennootschap met beperkte aansprakelijkheid）。 于2014年5月28日，根据公证转换契约及修订，该公司转为上市有限责任公司（naamloze vennootschap）。 该公司是一家处于商业阶段的、全球性的、完全整合的生物制药公司，开发用于治疗严重自身免疫性疾病的差异化疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.007923},{"month":2,"riseRate":0.333333,"avgChangeRate":0.026997},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.02217},{"month":4,"riseRate":0.777778,"avgChangeRate":0.0372},{"month":5,"riseRate":0.555556,"avgChangeRate":0.061118},{"month":6,"riseRate":0.8,"avgChangeRate":0.059431},{"month":7,"riseRate":0.6,"avgChangeRate":0.070059},{"month":8,"riseRate":0.7,"avgChangeRate":0.036587},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020239},{"month":10,"riseRate":0.666667,"avgChangeRate":0.037064},{"month":11,"riseRate":0.777778,"avgChangeRate":0.116374},{"month":12,"riseRate":0.444444,"avgChangeRate":0.116024}],"exchange":"NASDAQ","name":"Argenx SE","nameEN":"Argenx SE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Argenx SE,ARGX,Argenx SE股票,Argenx SE股票老虎,Argenx SE股票老虎国际,Argenx SE行情,Argenx SE股票行情,Argenx SE股价,Argenx SE股市,Argenx SE股票价格,Argenx SE股票交易,Argenx SE股票购买,Argenx SE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Argenx SE(ARGX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Argenx SE(ARGX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}